### ðŸ«  Cardiology: Dual Antiplatelet Therapy After Drugâ€‘Eluting Stent

#### âœ… True Statements
1. After **percutaneous coronary intervention (PCI)** with a **drugâ€‘eluting stent** for **stable ischemic heart disease**, **dual antiplatelet therapy (DAPT)** with **aspirin** plus a **P2Y12 receptor inhibitor** should be continued for **at least 6Â months**.
2. In patients with a **high risk for stent thrombosis**â€”such as **depressed left ventricular (LV) systolic function**, **diabetes mellitus**, or **saphenous vein graft stenting**â€”continuation of **dual antiplatelet therapy** beyond 6Â months is reasonable when bleeding risk is acceptable.
3. In patients at **high risk for bleeding**, it may be reasonable to **discontinue aspirin after 1â€“3Â months** of DAPT and continue the **P2Y12 inhibitor** alone to reduce bleeding risk.
4. Alternatively, for patients with **high bleeding risk** or **overt bleeding**, **discontinuation of the P2Y12 inhibitor after 3Â months** of DAPT with continuation of **lifelong aspirin** is reasonable.
5. Following any **coronary revascularization**, **lifelong singleâ€‘antiplatelet therapy with aspirin** is recommended to reduce late stent thrombosis and subsequent ischemic events.

#### ðŸ’¬ Extra
1. A 6â€‘month minimum course of DAPT after drugâ€‘eluting stent implantation in stable angina carries a **classÂ I (levelÂ A)** recommendation in the 2021 ACC/AHA/SCAI coronary revascularization guideline.
2. Examples of high thrombosis risk factors include **reduced LV ejection fractionÂ (<40%)**, **diabetes mellitus**, and **saphenous vein graft stenting**.
3. Trials evaluating â€œaspirinâ€‘freeâ€ strategies demonstrate lower bleeding rates while maintaining acceptable antiplatelet efficacy when a potent **P2Y12 inhibitor** is continued.
4. Continuing **aspirin alone** maintains coronary protection and is preferred over P2Y12 inhibitor monotherapy when the bleeding risk of P2Y12 inhibition outweighs thrombotic concerns.
5. **AspirinÂ 81Â mg daily** remains the cornerstone of secondary prevention after PCI.

#### ðŸ”· Tags
#Cardiology #AmbulatoryCare #PatientOver65 #HighValueCare #DualAntiplateletTherapy #PercutaneousCoronaryIntervention #StableIschemicHeartDisease

#### ðŸ“™ Reference
LawtonÂ JS, Tamisâ€‘HollandÂ JE, BangaloreÂ S, etâ€¯al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization. *J Am Coll Cardiol*.Â 2022;79:e21â€‘e129. PMID:Â 34895950 Â  DOI:10.1016/j.jacc.2021.09.006

#### ðŸ†” Question ID
CVMCQ24016

#### ðŸ•’ Last Updated
FebruaryÂ 2025

---

#### ðŸ“– Related Text
MKSAPÂ 19: Cardiovascular Medicine â€” Coronary Revascularization, Antiplatelet and Anticoagulant Therapy After Revascularization

---

### ðŸ“˜ Related Text Derivations

#### âœ… True Statements
1. **Indefinite antiplatelet therapy** is recommended for **all patients** after **percutaneous coronary intervention (PCI)** performed for **stable angina**.
2. After **bareâ€‘metal stent** implantation for **stable coronary disease**, **dual antiplatelet therapy** should be administered for a **minimum of 1Â month**.
3. In the setting of an **acute coronary syndrome (ACS)**, a **longer duration** of dual antiplatelet therapy is generally indicated than after PCI for stable disease.
4. Patients with **atrial fibrillation** who undergo PCI should receive **triple therapy** with an **oral anticoagulant, aspirin, and clopidogrel** for **1â€“4Â weeks**, after which **aspirin is discontinued**.
5. Between **6 and 12Â months** after PCI in such patients, **clopidogrel can be stopped**, and **lifelong oral anticoagulant monotherapy** continued if bleeding risk is high.
6. **Direct oral anticoagulants (DOACs)** are **contraindicated** in patients with a **mechanical heart valve**; these patients should receive **warfarin plus clopidogrel** when dual antiplatelet therapy is indicated.
7. Routine **periodic ischemic or anatomic testing** is **not recommended** in patients with **stable chronic coronary disease** after revascularization if clinical or functional status is unchanged.
8. After **coronary artery bypass grafting (CABG)** for **stable coronary artery disease**, **12Â months of dual antiplatelet therapy** may improve **saphenous vein graft patency**.
9. **Clopidogrel** is dosed with a **300 â€“ 600 mg loading dose** followed by a **75 mg once-daily maintenance dose** when used after percutaneous coronary intervention (PCI) for coronary artery disease (CAD).
10. **Ticagrelor** is administered as a **180 mg loading dose** and then **90 mg twice daily** for maintenance therapy in acute coronary syndrome (ACS).
11. **Prasugrel** is given as a **60 mg loading dose** followed by a **10 mg once-daily maintenance dose**, with a reduced **5 mg once-daily** maintenance dose recommended for patients who weigh **< 60 kg** or are **â‰¥ 75 years old**.
12. **All P2Yâ‚â‚‚ inhibitors (clopidogrel, ticagrelor, and prasugrel) have an adverse effect of increased bleeding risk.**
13. **Ticagrelor** can cause **dyspnea** in addition to bleeding risk.
14. **A known allergy** to any specific P2Yâ‚â‚‚ inhibitor is a **contraindication** to its use.
15. **Prasugrel is contraindicated** in patients with a **history of transient ischemic attack (TIA) or stroke**, and carries a **black-box warning for significant, sometimes fatal, bleeding**.

#### ðŸ’¬ Extra
1. AspirinÂ 81â€“100â€¯mg daily is the standard lifelong therapy used after PCI.
2. Bareâ€‘metal stents have lower late thrombosis risk, allowing abbreviated DAPT.
3. Plaque instability during ACS increases thrombogenicity, justifying extended therapy.
4. Early discontinuation of aspirin reduces gastrointestinal bleeding while maintaining stroke and myocardial infarction prevention.
5. Continuing only the oral anticoagulant balances stroke prevention with lower hemorrhagic risk.
6. The REâ€‘ALIGN trial showed excess thrombotic events and bleeding with DOACs in mechanical valves.
7. The 2021 ACC/AHA guideline labels routine stress testing in asymptomatic postâ€‘PCI patients as **low value care**.
8. Vein graft failure is most common within the first year, and DAPT may improve graft longevity.
9. Clopidogrel is also the preferred alternative in ACS when ticagrelor / prasugrel are not tolerated, unavailable, or contraindicated.
10. The weight- and age-adjusted prasugrel dose aims to lower bleeding risk in lighter or older patients.
11. The mechanism of ticagrelor-related dyspnea is thought to be adenosine-mediated.
12. The FDA black-box warning recommends avoiding prasugrel in patients with active pathologic bleeding or prior cerebrovascular events to prevent catastrophic hemorrhage.

#### ðŸ”· Tags
#AntiplateletTherapy #BleedingRisk #PercutaneousCoronaryIntervention #AtrialFibrillation #TripleTherapy #OralAnticoagulation #BareMetalStent #CoronaryArteryBypassGraft #ChronicCoronaryDisease

---

#### ðŸ—¾ Supplemental Table

<!-- P2Y12 Inhibitors Used in the Treatment of Patients With Coronary Artery Disease Undergoing Percutaneous Intervention -->
<table>
  <thead>
    <tr>
      <th>Drug</th>
      <th>Indications</th>
      <th>Loading&nbsp;Dose</th>
      <th>Maintenance&nbsp;Dose</th>
      <th>Adverse&nbsp;Effects</th>
      <th>Contraindications</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Clopidogrel</td>
      <td>
        Stable CAD treated with PCI<br/>
        ACS treated with fibrinolytic therapy or CABG<br/>
        Alternate in other ACS when prasugrel/ticagrelor unavailable/not tolerated/contraindicated
      </td>
      <td>300â€“600&nbsp;mg</td>
      <td>75&nbsp;mg/d</td>
      <td>Increased bleeding risk</td>
      <td>Known allergy to the drug</td>
    </tr>
    <tr>
      <td>Ticagrelor</td>
      <td>
        ACS treated with PCI or CABG<br/>
        ACS without planned intervention
      </td>
      <td>180&nbsp;mg</td>
      <td>90&nbsp;mg twice daily</td>
      <td>Increased bleeding risk, dyspnea</td>
      <td>Known allergy to the drug</td>
    </tr>
    <tr>
      <td>Prasugrel</td>
      <td>ACS treated with PCI</td>
      <td>60&nbsp;mg</td>
      <td>10&nbsp;mg/d<sup>a</sup></td>
      <td>Increased bleeding risk</td>
      <td>Known allergy to the drug, previous transient ischemic attack/stroke<sup>b</sup></td>
    </tr>
  </tbody>
</table>
<p><strong>Footnotes</strong></p>
<ol>
  <li><sup>a</sup> Prasugrel, 5&nbsp;mg/d, should be considered for those weighing less than 60&nbsp;kg (132&nbsp;lb) or age&nbsp;â‰¥75&nbsp;y.</li>
  <li><sup>b</sup> Prasugrel carries a black box warning for significant, sometimes fatal, bleeding and is contraindicated in patients with active pathologic bleeding or a history of transient ischemic attack or stroke.</li>
</ol>
<p><em>Abbreviations:</em> ACS&nbsp;=&nbsp;acute coronary syndrome; CABG&nbsp;=&nbsp;coronary artery bypass graft; CAD&nbsp;=&nbsp;coronary artery disease; PCI&nbsp;=&nbsp;percutaneous coronary intervention.</p>

